Dynavax Technologies Corp. (DVAX)
ROA
Obliczenia
|
2023/Q4 (31 gru 2023) |
2023/Q3 (30 wrz 2023) |
2023/Q2 (30 cze 2023) |
2023/Q1 (31 mar 2023) |
2022/Q4 (31 gru 2022) |
2022/Q3 (30 wrz 2022) |
2022/Q2 (30 cze 2022) |
2022/Q1 (31 mar 2022) |
||
|---|---|---|---|---|---|---|---|---|---|
| Zysk netto (ttm) | w tys. USD | -6 389 | 60 973 | 110 489 | 235 813 | 292 873 | 320 905 | 228 666 | 104 051 |
| Aktywa razem | w tys. USD | 997 096 | 972 933 | 936 432 | 969 922 | 985 850 | 999 337 | 1 023 000 | 1 008 980 |
| ROA | -0,64% | 6,27% | 11,80% | 24,31% | 29,71% | 32,11% | 22,35% | 10,31% |
2023/Q4 obliczenia
ROA = Zysk netto (ttm) ÷ Aktywa razem
= $-6 389K ÷ $997 096K
= -0,64%
Analiza porównawcza
2023/Q4
Nazwa spółki
Symbol
ROA
Dynavax Technologies Corp.
DVAX
-0,64%
Amphastar Pharmaceuticals Inc
AMPH
9,09%
Arcus Biosciences Inc
RCUS
-28,04%
Catalyst Pharmaceuticals Inc
CPRX
15,19%
Ironwood Pharmaceuticals Inc
IRWD
-212,76%
Ligand Pharmaceuticals, Inc.
LGND
6,63%
Medifast Inc
MED
32,08%
Myriad Genetics, Inc.
MYGN
-22,97%
Pacira BioSciences Inc
PCRX
2,66%
Supernus Pharmaceuticals Inc
SUPN
0,10%
Xencor Inc
XNCR
-13,23%